Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1150 mg double-blinded secukinumab1件: Secukinumab1件: D09967 (Name: Secukinumab)1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271
2150 mg open-label secukinumab1件: Secukinumab1件: D09967 (Name: Secukinumab)1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271
3300 mg double-blinded secukinumab1件: Secukinumab1件: D09967 (Name: Secukinumab)1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271
4SECUKINUMAB1件: Secukinumab1件: D09967 (Name: Secukinumab)1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬8件: 13, 37, 41, 46, 107, 160, 269, 271
5Secukinumab (150 mg)1件: Secukinumab1件: D09967 (Name: Secukinumab)1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271
6Secukinumab (75 mg)1件: Secukinumab1件: D09967 (Name: Secukinumab)1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271
7Secukinumab (AIN457)1件: Secukinumab1件: D09967 (Name: Secukinumab)1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 46
8Secukinumab (AIN457) 150 mg s.c.1件: Secukinumab1件: D09967 (Name: Secukinumab)1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271
9Secukinumab 150 mg1件: Secukinumab1件: D09967 (Name: Secukinumab)1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 41
10Secukinumab 150 mg (2 injections per dose1件: Secukinumab1件: D09967 (Name: Secukinumab)1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 269
11Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.1件: Secukinumab1件: D09967 (Name: Secukinumab)1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271
12Secukinumab 150 mg/1 mL Solution for injection1件: Secukinumab1件: D09967 (Name: Secukinumab)1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬2件: 37, 271
13Secukinumab 150 mg/ml1件: Secukinumab1件: D09967 (Name: Secukinumab)1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271
14Secukinumab 150 milligram [Cosentyx]1件: Secukinumab1件: D09967 (Name: Secukinumab)1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271
15Secukinumab 150mg1件: Secukinumab1件: D09967 (Name: Secukinumab)1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 37
16Secukinumab 300 mg1件: Secukinumab1件: D09967 (Name: Secukinumab)1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 41
17Secukinumab 300 mg, s.c.1件: Secukinumab1件: D09967 (Name: Secukinumab)1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 41
18Secukinumab 300mg1件: Secukinumab1件: D09967 (Name: Secukinumab)1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 37
19Secukinumab 75 mg/0.5 ml Solution for injection1件: Secukinumab1件: D09967 (Name: Secukinumab)1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271
20Secukinumab Injection1件: Secukinumab1件: D09967 (Name: Secukinumab)1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 160